Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

dMed Completes $100 Million Financing for China-US CRO Operations

publication date: Dec 17, 2020

dMed, a Shanghai-headquartered clinical CRO, completed a $100 million C round led by Fidelity Management & Research Company. dMed claims a strong presence in clinical and regulatory services especially in China and the US. The company said the financing would lead to an IPO in the future. dMed calls itself a "next-gen" clinical CRO with efficient operations, IT services and expertise in cross-border global trials. The company was founded in 2016 by Lingshi Tan, who was previously general manager of China R&D for Pfizer. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital